{"id":"W4396935701","doi":"10.1016/j.clcc.2024.05.002","title":"A Phase II, Open-Label, Randomized Trial of Durvalumab With Olaparib or Cediranib in Patients With Mismatch Repair—Proficient Colorectal or Pancreatic Cancer","year":2024,"lang":"en","type":"article","venue":"Clinical Colorectal Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ontario Institute for Cancer Research; University Health Network; Princess Margaret Cancer Centre","funders":"Institute of Genetics; Genentech; Servier; Astellas Pharma; Eisai; Seagen; Sociedad Española de Oncología Médica; Mirati Therapeutics; Regeneron Pharmaceuticals; Array BioPharma; Karyopharm Therapeutics; Daiichi Sankyo Europe; Iterion Therapeutics; Sanofi; GlaxoSmithKline; Celgene; Symphogen; Bristol-Myers Squibb; American Association for Cancer Research; AstraZeneca; Pfizer; Amgen","keywords":"Medicine; Olaparib; Durvalumab; Colorectal cancer; Oncology; Randomized controlled trial; Internal medicine; Open label; Cetuximab; Nivolumab; Cancer","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002153553,0.0005035782,0.002546462,0.0001991608,0.0001380591,0.00007497646,0.0003396372,0.000321446,0.001819559],"category_scores_gemma":[0.0006371114,0.0002619568,0.0003453703,0.001394724,0.0009737737,0.0002131307,0.0001497686,0.0006561264,0.000004894655],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005953893,"about_ca_system_score_gemma":0.003643159,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002044567,"about_ca_topic_score_gemma":0.003741364,"domain_scores_codex":[0.9951614,0.0004913287,0.001900576,0.001025432,0.0008283668,0.0005929237],"domain_scores_gemma":[0.996998,0.001492477,0.0004798516,0.0004027468,0.000360733,0.000266199],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9636096,0.009090897,0.007208614,0.0004524296,0.002049156,0.0001608206,0.0006069546,0.000004176427,0.0002613066,0.00001286156,0.002044963,0.01449823],"study_design_scores_gemma":[0.9080386,0.07877181,0.004494414,0.002972605,0.001408454,0.00001378689,0.0001020855,0.001217227,0.0006897195,0.000006899376,0.001840316,0.0004440625],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9853548,0.001905029,0.00001137748,0.0006343209,0.001556598,0.009625539,0.0002399464,0.0001466305,0.0005257421],"genre_scores_gemma":[0.9922277,0.001278408,0.0004587549,0.0005569993,0.0003556131,0.003339715,0.00006766766,0.00009871882,0.00161639],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06968091,"threshold_uncertainty_score":0.9999833,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05931110347040201,"score_gpt":0.4103780571519678,"score_spread":0.3510669536815658,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}